Education
About Us
Working with TipRanks
Follow Us
Heidelberg Pharma AG (DE:HPHA)
:HPHA
HPHA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€2.11 - €3.25
Previous CloseN/A
Volume3.96K
Average Volume (3M)4.85K
Market Cap
€121.63M
Enterprise ValueN/A
Total Cash (Recent Filing)€32.65M
Total Debt (Recent Filing)€5.24M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Mar 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding46,601,097
10 Day Avg. Volume7,740
30 Day Avg. Volume4,847
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.45
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
HPHA FAQ
What was Heidelberg Pharma AG’s price range in the past 12 months?
Heidelberg Pharma AG lowest stock price was €2.11 and its highest was €3.25 in the past 12 months.
What is Heidelberg Pharma AG’s market cap?
Heidelberg Pharma AG’s market cap is €121.63M.
When is Heidelberg Pharma AG’s upcoming earnings report date?
Heidelberg Pharma AG’s upcoming earnings report date is Mar 21, 2025 which is in 9 days.
How were Heidelberg Pharma AG’s earnings last quarter?
Currently, no data Available
Is Heidelberg Pharma AG overvalued?
According to Wall Street analysts Heidelberg Pharma AG’s price is currently Overvalued.
Does Heidelberg Pharma AG pay dividends?
Heidelberg Pharma AG does not currently pay dividends.
What is Heidelberg Pharma AG’s EPS estimate?
Heidelberg Pharma AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heidelberg Pharma AG have?
Heidelberg Pharma AG has 46,601,097 shares outstanding.
What happened to Heidelberg Pharma AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Heidelberg Pharma AG?
Currently, no hedge funds are holding shares in DE:HPHA
---
Heidelberg Pharma AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
-18.78%
12-Months-Change
Fundamentals
Return on Equity
-42.99%
Trailing 12-Months
Asset Growth
-11.51%
Trailing 12-Months
Company Description
Heidelberg Pharma AG
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through following business divisions: Customer Specific Research, Diagnostics and Therapeutics.
---
Technical Analysis
---